Attovia Therapeutics, Inc.

NASDAQ:ATTO

Biotechnology

Healthcare
$15.53 -1.20%

-$0.18 today

Market cap
$709.92M
Beta
0.00
P/E (TTM)
-15.9
EPS (TTM)
-$0.86
52W Low $14.23High $28.00

Volume 0.34M

Average 0.45M

ATTO Income Before Tax

Profit after all operating and non-operating items but before income tax.

Attovia Therapeutics, Inc.NASDAQ: ATTO

Income Before Tax · Q2 FY2026 · quarter ended Jun 2026

Income before tax of -$20.69M in Q2 FY2026

Q2 FY2026 income before tax was -$20.69M.

Context

  • Income before tax amounted to 4490.9% of revenue in FY2025.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$20.69M-10.9% QoQ
Last fiscal yearDec 2025
-$60.63M-52.3% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-52.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(60.63M) USD
Year-over-year change
-52.3%

Income Before Tax vs competitors

How ATTO compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -52.3% is the 6th highest of 10, against a peer median of -39.7%.
  • Income before tax amounts to 4490.9% of revenue for ATTO, versus a peer median of 796.2%.
ATTO Competitors
Income Before Tax for ATTO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
QTTBQ32 Bio Inc.LTM Mar 2026$33.24M USD+157.0%—61.9%
ANABAnaptysBio, Inc.LTM Mar 2026-$26.63M USD+81.1%—11.5%
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024-€46.26M EUR-285.2%——
CNTBConnect Biopharma Holdings LimitedFY2025-$55.28M USD-258.9%—86379.7%
ATTOAttovia Therapeutics, Inc.FY2025-$60.63M USD-52.3%—4490.9%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-$69.66M USD+46.5%—832.6%
ZURAZura Bio LimitedLTM Mar 2026-$75.43M USD-21.5%——
EVMNEvommune, Inc.LTM Mar 2026-$75.99M USD——759.9%
ORKAOruka Therapeutics, Inc.LTM Sep 2026-$152.57M USD-39.7%——
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026-$258.39M USD-75.2%——
ALMSAlumis Inc. Common StockLTM Jun 2026-$440.71M USD-86.7%—5957.2%
Peer median (excluding ATTO) —-39.7%—796.2%

Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2024
Dec 2024
FY2025
Dec 2025
Revenue01.35M
Cost of Revenue313K804K
Gross Profit(313K)546K
Gross Margin—40.4%
Research & Development33.86M54.15M
Selling, General & Admin7.38M13.55M
Operating Expenses41.24M67.71M
Depreciation & Amortization313K804K
EBITDA(41.24M)(66.36M)
EBITDA Margin—-4915.2%
Operating Income(41.55M)(67.16M)
Operating Margin—-4974.7%
Interest Income3.44M6.63M
Interest Expense00
Other Income / Expenses1.75M6.53M
Income Before Tax(39.8M)(60.63M)
Pre-Tax Margin—-4490.9%
Income Tax Expense00
Net Income(39.8M)(60.63M)
Net Margin—-4490.9%
EPS (Basic)(1.05)(1.42)
EPS (Diluted)(1.05)(1.42)
Weighted Avg Shares43.03M43.03M
Weighted Avg Shares (Diluted)43.03M43.03M

Attovia Therapeutics, Inc.

NASDAQ:ATTO

Intrinsic Alpha fair value

Locked

Current Price

$15.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.